Abstract
Matrix metalloproteinases (MMPs) are essential for the degradation and turnover of components of the extracellular matrix (ECM) and, when pathologically elevated, mediate connective tissue loss (including bone destruction) in various inflammatory and other diseases. Tetracyclines (TCs) are known inhibitors of mammalian-derived MMPs, and non-antibiotic formulations of Doxycycline are FDA-approved to treat periodontitis and the chronic inflammatory skin disease, rosacea. Because the C-11/ C-12 diketonic moiety of the tetracyclines is primarily responsible, through zinc-binding, for MMP inhibition, we have uniquely modified curcumin as a “core” molecule, since it contains a similar enolic system and is known to have beneficial effects in diseases where connective-tissue loss occurs. Specifically we have developed new congeners which exhibit improved zinc-binding and solubility, and potent reduction of excessive MMP levels and activity. We now describe a series of curcuminoid bi- and tri-carbonylmethanes in which all of these properties are substantially improved. An N-phenylaminocarbonyl derivative of bis-demethoxycurcumin (CMC2.24) was selected as the “lead” substance because it showed superior potency in vitro (i.e., the lowest IC50) against a series of neutral proteases (MMPs) associated with tissue erosion. Moreover, CMC2.24 administered to diabetic rats orally (30mg/kg), reduced the secretion of pathologically-excessive levels of MMP-9 to normal in cultured peritoneal macrophages with no evidence of toxicity. Thus, this (and other similar novel) compound(s) may be useful in various diseases of connective-tissue loss.
Keywords: Matrix metalloproteinases, chemically-modified-curcumin, connective tissue degradation, zinc-binding, enolic β-diketone moiety
Current Medicinal Chemistry
Title:Design, Synthesis and Biological Activity of New Polyenolic Inhibitors of Matrix Metalloproteinases: A Focus on Chemically-Modified Curcumins
Volume: 19 Issue: 25
Author(s): Yu Zhang, Ying Gu, Hsi-Ming Lee, Elena Hambardjieva, Kveta Vrankova, Lorne M. Golub and Francis Johnson
Affiliation:
Keywords: Matrix metalloproteinases, chemically-modified-curcumin, connective tissue degradation, zinc-binding, enolic β-diketone moiety
Abstract: Matrix metalloproteinases (MMPs) are essential for the degradation and turnover of components of the extracellular matrix (ECM) and, when pathologically elevated, mediate connective tissue loss (including bone destruction) in various inflammatory and other diseases. Tetracyclines (TCs) are known inhibitors of mammalian-derived MMPs, and non-antibiotic formulations of Doxycycline are FDA-approved to treat periodontitis and the chronic inflammatory skin disease, rosacea. Because the C-11/ C-12 diketonic moiety of the tetracyclines is primarily responsible, through zinc-binding, for MMP inhibition, we have uniquely modified curcumin as a “core” molecule, since it contains a similar enolic system and is known to have beneficial effects in diseases where connective-tissue loss occurs. Specifically we have developed new congeners which exhibit improved zinc-binding and solubility, and potent reduction of excessive MMP levels and activity. We now describe a series of curcuminoid bi- and tri-carbonylmethanes in which all of these properties are substantially improved. An N-phenylaminocarbonyl derivative of bis-demethoxycurcumin (CMC2.24) was selected as the “lead” substance because it showed superior potency in vitro (i.e., the lowest IC50) against a series of neutral proteases (MMPs) associated with tissue erosion. Moreover, CMC2.24 administered to diabetic rats orally (30mg/kg), reduced the secretion of pathologically-excessive levels of MMP-9 to normal in cultured peritoneal macrophages with no evidence of toxicity. Thus, this (and other similar novel) compound(s) may be useful in various diseases of connective-tissue loss.
Export Options
About this article
Cite this article as:
Zhang Yu, Gu Ying, Lee Hsi-Ming, Hambardjieva Elena, Vrankova Kveta, M. Golub Lorne and Johnson Francis, Design, Synthesis and Biological Activity of New Polyenolic Inhibitors of Matrix Metalloproteinases: A Focus on Chemically-Modified Curcumins, Current Medicinal Chemistry 2012; 19 (25) . https://dx.doi.org/10.2174/092986712802884295
DOI https://dx.doi.org/10.2174/092986712802884295 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biological Activities and In Silico Physico-Chemical Properties of 1,2,3- Triazoles Derived from Natural Bioactive Alcohols
Anti-Infective Agents Bone Marrow Stromal Cells as Targets for Gene Therapy
Current Gene Therapy Triamcinolone Acetonide Inhibits p38MAPK Activation and Neuronal Apoptosis in Early Diabetic Retinopathy
Current Molecular Medicine Differences and Similarities of Epothilones
Current Cancer Therapy Reviews Synthesis and Antitumor Evaluation of Novel N-substituted Norcantharidin Imidazolium Derivatives
Current Organic Synthesis Advances of Paclitaxel Formulations Based on Nanosystem Delivery Technology
Mini-Reviews in Medicinal Chemistry Endothelial Cell Targeted Molecular Imaging in Tumor Angiogenesis: Strategies and Current Status
Current Pharmaceutical Biotechnology Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology Relevance of Micrometastases and Targeting the Bone Marrow Niche with Zoledronic Acid in Breast Cancer
Current Cancer Therapy Reviews Gene Therapy and Biologic Therapy with Interleukin?4
Current Gene Therapy Recent Developments in Tumor Angiogenesis
Current Pharmaceutical Biotechnology CCNE1 Promotes Progression and is Associated with Poor Prognosis in Lung Adenocarcinoma
Current Pharmaceutical Biotechnology Ganoderma lucidum (Ling-zhi): The Impact of Chemistry on Biological Activity in Cancer
Current Bioactive Compounds Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery
Current Medicinal Chemistry TRPM8, a Sensor for Mild Cooling in Mammalian Sensory Nerve Endings
Current Pharmaceutical Biotechnology Current and Future Therapeutic Targets: A Review on Treating Head and Neck Squamous Cell Carcinoma
Current Cancer Drug Targets Initiation of the Immune Response by Extracellular Hsp72: Chaperokine Activity of Hsp72
Current Immunology Reviews (Discontinued) Dietary Agents for Prostate Cancer Chemoprevention: An Overview
Current Cancer Therapy Reviews A Transporter Gene (Sodium Iodide Symporter) for Dual Purposes in Gene Therapy: Imaging and Therapy
Current Gene Therapy Effects of Highly Active Antiretroviral Therapy on HIV-1-Associated Oral Complications
Current HIV Research